Perrigo third-quarter sales up 13% to $185.3 mil.; soft analgesic sales lead to income drop.
This article was originally published in The Tan Sheet
Executive SummaryPERRIGO THIRD-QUARTER SALES RISE 13% TO $185.3 MIL., boosted by a more than 20% increase in cough/cold products. The over 20% gain was generated by a "stronger end" to the cough and cold season, the company said in a May 9 release. However, net income was down 13.9% to $11.4 mil. in the quarter from $13.3 mil. in the comparable period of fiscal 1994
You may also be interested in...
Johnson & Johnson has achieved exceptional growth in recent years, and a raft of new products is set to sustain it further.
Bayer’s drive to lead a new market opportunity in Europe for histology-independent cancer agents like Vitrakvi has been set back by interim decisions from the UK’s NICE and Germany’s IQWiG, but there is a now a clear pathway to follow.
Performance-based managed entry agreements need to be made more effective, but this can only happen if countries relax their stance on confidentiality and share information on MEAs amongst themselves, says a working paper from the OECD.